2. Academic Validation
  3. Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders

Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders

  • Rev Neurol (Paris). 2022 May;178(5):460-471. doi: 10.1016/j.neurol.2022.03.010.
M Lopez-Cuina 1,  W G Meissner 2
Affiliations

Affiliations

  • 1 Department of Neurology, Hospital Universitario Reina Sofía, 14004 Cordoba, Spain; University Bordeaux, CNRS, IMN, UMR 5293, 33000 Bordeaux, France.
  • 2 University Bordeaux, CNRS, IMN, UMR 5293, 33000 Bordeaux, France; CHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, IMNc, 33000 Bordeaux, France; Department of Medicine, University of Otago, Christchurch, and New Zealand Brain Research Institute, Christchurch, New Zealand. Electronic address: wassilios.meissner@chu-bordeaux.fr.
PMID: 35562199 DOI: 10.1016/j.neurol.2022.03.010
Abstract

The two commonest groups of neurodegenerative disorders causing movement disorders are synucleinopathies and tauopathies. These disorders are characterised by the accumulation of abnormally misfolded forms of α-synuclein and tau proteins. Our current understanding of their pathogenesis suggests that extracellular forms of these proteins are of major relevance to the mechanism of pathology propagation throughout the brain and disease progression. The most novel approaches to find disease-modifying therapies aim to reduce or block these forms of tau and α-synuclein. This article reviews therapeutic strategies targeting α-synuclein and Tau Protein which have entered clinical development.

Keywords

Alpha-synuclein; Neurodegeneration; Tau; Therapeutic development.

Figures
Products